HomeProductsBuilding BlocksCarbocyclic ScaffoldsCyclohexanesSemustine
Chemical structure of CAS 13909-09-6

Semustine

In Stock•Starting at $31 for 5 mg•Purity ≥ 98%
CAS No.13909-09-6
MDL No.MFCD00133811
MFC10H18ClN3O2
MW247.72
InChI KeyFVLVBPDQNARYJU-UHFFFAOYSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
5 mg98%$31In Stock
25 mg98%$86In Stock
100 mg98%$266In Stock
250 mg98%$477In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

Semustine is an organochlorine compound derived from urea, with the two hydrogens on one amino group replaced by nitroso and 2-chloroethyl groups, and one hydrogen on the other amino group replaced by a 4-methylcyclohexyl group. It functions as an antineoplastic, carcinogenic, and alkylating agent, and is a member of the N-nitrosoureas.

CAS No.13909-09-6
Product NameSemustine

Associated Conditions

neoplasm
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Quantification of meCCNU-induced dG-dC crosslinks in oligonucleotide duplexes by liquid chromatography/electrospray ionization tandem mass spectrometry.

Rapid communications in mass spectrometry : RCM • Vol. 25, Issue 14 • 2011
PMID: 21698685DOI: 10.1002/rcm.5064

Nitrosourea chemotherapeutic agents: 1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea.

Report on carcinogens : carcinogen profiles • Vol. 12 • 2011
PMID: 21860520

Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas.

Therapeutics and clinical risk management • Vol. 3, Issue 5 • 2007
PMID: 18472995PMC: PMC2376068

Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01.

Journal of the National Cancer Institute • Vol. 96, Issue 15 • 2004
PMID: 15292384DOI: 10.1093/jnci/djh220

Documentation

Similar Products